<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T14:12:20Z</responseDate>
  <request identifier="oai:figshare.com:article/33959907" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33959907</identifier>
        <datestamp>2026-09-21T20:11:37Z</datestamp>
        <setSpec>category_1</setSpec>
        <setSpec>category_146</setSpec>
        <setSpec>category_14</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_128</setSpec>
        <setSpec>portal_63</setSpec>
        <setSpec>item_type_2</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Hydrodynamic
Cell Capture and Release Microfluidic
Chip for Cancer Drug Screening</dc:title>
          <dc:creator>Xuefeng Wang (113961)</dc:creator>
          <dc:creator>Wei Li (7081)</dc:creator>
          <dc:creator>Xiaoling Zhang (420384)</dc:creator>
          <dc:creator>Jun Yang (2084)</dc:creator>
          <dc:creator>Ning Hu (331646)</dc:creator>
          <dc:subject>Biophysics</dc:subject>
          <dc:subject>Space Science</dc:subject>
          <dc:subject>Molecular Biology</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Hematology</dc:subject>
          <dc:subject>optimal design parameters</dc:subject>
          <dc:subject>concentration gradient generator</dc:subject>
          <dc:subject>0 ± 8</dc:subject>
          <dc:subject>equivalent resistance model</dc:subject>
          <dc:subject>reverse flow directions</dc:subject>
          <dc:subject>lowest flow resistance</dc:subject>
          <dc:subject>highest flow resistance</dc:subject>
          <dc:subject>main channel switches</dc:subject>
          <dc:subject>main channel exhibits</dc:subject>
          <dc:subject>reverse release modes</dc:subject>
          <dc:subject>reverse release mode</dc:subject>
          <dc:subject>cellular gene expression</dc:subject>
          <dc:subject>10 μm measured</dc:subject>
          <dc:subject>cells flow along</dc:subject>
          <dc:subject>hydrodynamic cell capture</dc:subject>
          <dc:subject>different drug concentrations</dc:subject>
          <dc:subject>microfluidic device integrating</dc:subject>
          <dc:subject>9 ± 3</dc:subject>
          <dc:subject>0 ± 4</dc:subject>
          <dc:subject>release microfluidic chip</dc:subject>
          <dc:subject>based drug screening</dc:subject>
          <dc:subject>8 %, respectively</dc:subject>
          <dc:subject>forward capture mode</dc:subject>
          <dc:subject>50 &lt;/ sub</dc:subject>
          <dc:subject>using k562 cells</dc:subject>
          <dc:subject>flow resistance</dc:subject>
          <dc:subject>main channel</dc:subject>
          <dc:subject>reverse release</dc:subject>
          <dc:subject>drug screening</dc:subject>
          <dc:subject>cell capture</dc:subject>
          <dc:subject>investigating drug</dc:subject>
          <dc:subject>generated using</dc:subject>
          <dc:subject>constructed based</dc:subject>
          <dc:subject>channel width</dc:subject>
          <dc:subject>approximately 10</dc:subject>
          <dc:subject>79 μm</dc:subject>
          <dc:subject>forward capture</dc:subject>
          <dc:subject>capture efficiency</dc:subject>
          <dc:subject>k562 cells</dc:subject>
          <dc:subject>four concentrations</dc:subject>
          <dc:subject>chip microplate</dc:subject>
          <dc:subject>chip ic</dc:subject>
          <dc:subject>release efficiency</dc:subject>
          <dc:subject>release efficiencies</dc:subject>
          <dc:subject>myc &lt;/</dc:subject>
          <dc:subject>lyn &lt;/</dc:subject>
          <dc:subject>efficient release</dc:subject>
          <dc:description>Microfluidic chip-based drug screening has attracted
increasing
attention owing to its miniaturization, automation, high throughput,
simple operation, and excellent biocompatibility. Efficient release
of target cells after co-culture with different drug concentrations
is critical for investigating drug-induced alterations in cellular
gene expression and enhancing microfluidic screening performance.
In this study, a direction-sensitive microstructure with adaptive
flow resistance regulation was constructed based on a fluidic-circuit-equivalent
resistance model. This structure generated distinct distributions
under forward and reverse flow directions, achieving efficient cell
capture and release. Guided by theoretical analysis and simulation
optimization, a microfluidic device integrating a concentration gradient
generator, trap array, and flow resistance-regulating microchannels
was fabricated. By simply switching the driving direction, the device
can conveniently switch between forward capture and reverse release
modes with high stability. In forward capture mode, the main channel
exhibits the lowest flow resistance, and cells flow along the main
channel and are captured in the traps. In reverse release mode, the
main channel switches to the highest flow resistance, and cells in
the traps are efficiently released backward along bypass channels
to the collection outlet without recapture. Using K562 cells, the
effects of channel width on cell capture and release efficiencies
were investigated to determine the optimal design parameters. Finally,
the device achieved a capture efficiency of 92.0 ± 4.4% and a
release efficiency of 70.0 ± 8.6%, with maximum values of 97.2%
and 87.8%, respectively. To further verify the device’s applicability
for drug screening, four concentrations of nilotinib were generated
using the device. After K562 cells were cultured under the four concentrations
for 48 h, the on-chip IC&lt;sub&gt;50&lt;/sub&gt; of nilotinib against K562 cells
was determined to be approximately 10.79 μM, close to the result
of 14.10 μM measured in the off-chip microplate. Subsequently,
the treated cells were collected after reverse release and subjected
to RNA-seq. The results showed that 20 μM nilotinib treatment
significantly downregulated the expression of &lt;i&gt;MYC&lt;/i&gt;, &lt;i&gt;LYN&lt;/i&gt;, and &lt;i&gt;BCL2L12&lt;/i&gt;, which are related
to BCR-ABL signaling, by 18.3-fold, 3.6-fold, and 4.7-fold, respectively.
Meanwhile, the treatment inhibited the viability of K562 cells to
23.9 ± 3.5%.</dc:description>
          <dc:date>2026-09-21T00:00:00Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Media</dc:type>
          <dc:identifier>10.1021/acs.analchem.6c03273.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/media/Hydrodynamic_Cell_Capture_and_Release_Microfluidic_Chip_for_Cancer_Drug_Screening/33959907</dc:relation>
          <dc:rights>CC BY-NC 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
